Dermatitis News

Patients with atopic dermatitis who were treated with internet-delivered cognitive behavioral therapy had a significant reduction in symptoms, according to a study.

Upadacitinib, an oral JAK inhibitor, was effective in treating moderate to severe atopic dermatitis in two phase 3 clinical trials.

A childhood diagnosis of atopic dermatitis was associated with lower attainment of secondary education but not higher education, according to a population-based study.

WAILEA, Hawaii — Dupilumab is an important treatment for patients with atopic dermatitis, but there can be ocular consequences, which themselves need treatment.

Itch can have a substantial impact on quality of life, but is difficult to quantify, according to a research article in Science Advances.

Gusacitinib produced significant and rapid improvement of severity and pain in patients with moderate to severe chronic hand eczema, according to a study presented at AAD VMX 2021.

In this video, Michael J. Cork, BSC, MB, PhD, FRCP, discusses how data from posters being presented at AAD VMX 2021 on dupilumab reinforce his experience of how life-changing dupilumab treatment can be in children with atopic dermatitis.

In this video from AAD VMX 2021, Andrew Blauvelt, MD, MBA, discusses his presentation on the necessity of laboratory testing for adult patients on long-term dupilumab treatment for moderate to severe atopic dermatitis.

Etrasimod, an investigational drug for moderate to severe atopic dermatitis, demonstrated statistically significant improvements in a phase 2b clinical trial, according to a study presented at AAD VMX 2021.

Long-term use of tralokinumab is safe and efficacious in the treatment of atopic dermatitis, according to a presentation at AAD VMX 2021.